ESMO 2021 | Next steps for radiopharmaceuticals in prostate cancer

Silke Gillessen, MD, PhD, University of Lugano, Lugano, Switzerland and the Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, provides an overview of the state of the art in the use of radiopharmaceutical products for the treatment of prostate cancer, touching on the recently published Phase III VISION study (NCT03511664) evaluating 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer as well as the importance of obtaining long-term follow-up data on potential toxicity. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.